PortalPublikationenSustained prognostic impact of circulating tumor cell status...

Sustained prognostic impact of circulating tumor cell status and kinetics upon further progression of metastatic breast cancer

Standard

Sustained prognostic impact of circulating tumor cell status and kinetics upon further progression of metastatic breast cancer. / Jauch, Sarah F; Riethdorf, Sabine; Sprick, Martin R; Schütz, Florian; Schönfisch, Birgitt; Brucker, Sara Y; Deutsch, Thomas M; Nees, Juliane; Saini, Massimo; Becker, Lisa M; Burwinkel, Barbara; Sinn, Peter; Marmé, Frederik; Pantel, Klaus; Jäger, Dirk; Sohn, Christof; Trumpp, Andreas; Wallwiener, Markus; Schneeweiss, Andreas.

in: BREAST CANCER RES TR, Jahrgang 173, Nr. 1, 01.2019, S. 155-165.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Jauch, SF, Riethdorf, S, Sprick, MR, Schütz, F, Schönfisch, B, Brucker, SY, Deutsch, TM, Nees, J, Saini, M, Becker, LM, Burwinkel, B, Sinn, P, Marmé, F, Pantel, K, Jäger, D, Sohn, C, Trumpp, A, Wallwiener, M & Schneeweiss, A 2019, 'Sustained prognostic impact of circulating tumor cell status and kinetics upon further progression of metastatic breast cancer', BREAST CANCER RES TR, Jg. 173, Nr. 1, S. 155-165. https://doi.org/10.1007/s10549-018-4972-y

APA

Jauch, S. F., Riethdorf, S., Sprick, M. R., Schütz, F., Schönfisch, B., Brucker, S. Y., Deutsch, T. M., Nees, J., Saini, M., Becker, L. M., Burwinkel, B., Sinn, P., Marmé, F., Pantel, K., Jäger, D., Sohn, C., Trumpp, A., Wallwiener, M., & Schneeweiss, A. (2019). Sustained prognostic impact of circulating tumor cell status and kinetics upon further progression of metastatic breast cancer. BREAST CANCER RES TR, 173(1), 155-165. https://doi.org/10.1007/s10549-018-4972-y

Vancouver

Jauch SF, Riethdorf S, Sprick MR, Schütz F, Schönfisch B, Brucker SY et al. Sustained prognostic impact of circulating tumor cell status and kinetics upon further progression of metastatic breast cancer. BREAST CANCER RES TR. 2019 Jan;173(1):155-165. https://doi.org/10.1007/s10549-018-4972-y

Bibtex

@article{31368e36cfff4440bcf99769f3511772,
title = "Sustained prognostic impact of circulating tumor cell status and kinetics upon further progression of metastatic breast cancer",
abstract = "PURPOSE: Serial longitudinal enumeration of circulating tumor cells (CTCs) has shown its prognostic value on progression-free survival and overall survival (OS) in patients with stage IV breast cancer. This study prospectively evaluated the role of CTCs as a prognostic marker during further progression of metastatic breast cancer (MBC).METHODS: Among 476 MBC patients recruited between 2010 and 2015, the 103 patients with a known CTC status at baseline (CTCBL) and within 4 weeks of tumor progression (CTCPD) were included. Progressive disease (PD) was defined according to the Response Evaluation Criteria in Solid Tumors (RECIST, version 1.1). Using the CellSearch method, < 5 and ≥ 5 CTCs per 7.5 ml blood were determined as negative and positive, respectively. A shift in CTC status from baseline to progression ([Formula: see text] to [Formula: see text] and vice versa) was considered as alternating KineticsBL-PD.RESULTS: Median follow-up was 29.9 [21.2, 40.0] months. CTCPD positivity (37%, n = 38) was associated with a significantly shorter OS than CTCPD negativity (8.0 [5.1, 10.9] vs 22.6 [15.3, 39.8] months; P < 0.001). Alternating KineticsBL-PD was observed in 24% of the patients. This significantly changed the OS prediction of [Formula: see text] patients ([Formula: see text] vs [Formula: see text], 11.4 [9.7, not available (NA)] vs. 7.6 [4.4, 11.5] months; P = 0.044) and [Formula: see text] patients ([Formula: see text] vs. [Formula: see text], 8.4 [4.0, NA] vs. 22.6 [18.9, NA] months, respectively; P < 0.001). Prediction of survival was significantly improved (P = 0.002) by adding CTCPD status to clinicopathological characteristics and CTCBL status.CONCLUSIONS: CTC status upon further disease progression is a prognostic factor that could significantly improve well-established models. Thus, it represents a potential additional instrument supporting treatment decision.",
keywords = "Journal Article",
author = "Jauch, {Sarah F} and Sabine Riethdorf and Sprick, {Martin R} and Florian Sch{\"u}tz and Birgitt Sch{\"o}nfisch and Brucker, {Sara Y} and Deutsch, {Thomas M} and Juliane Nees and Massimo Saini and Becker, {Lisa M} and Barbara Burwinkel and Peter Sinn and Frederik Marm{\'e} and Klaus Pantel and Dirk J{\"a}ger and Christof Sohn and Andreas Trumpp and Markus Wallwiener and Andreas Schneeweiss",
year = "2019",
month = jan,
doi = "10.1007/s10549-018-4972-y",
language = "English",
volume = "173",
pages = "155--165",
journal = "BREAST CANCER RES TR",
issn = "0167-6806",
publisher = "Springer New York",
number = "1",

}

RIS

TY - JOUR

T1 - Sustained prognostic impact of circulating tumor cell status and kinetics upon further progression of metastatic breast cancer

AU - Jauch, Sarah F

AU - Riethdorf, Sabine

AU - Sprick, Martin R

AU - Schütz, Florian

AU - Schönfisch, Birgitt

AU - Brucker, Sara Y

AU - Deutsch, Thomas M

AU - Nees, Juliane

AU - Saini, Massimo

AU - Becker, Lisa M

AU - Burwinkel, Barbara

AU - Sinn, Peter

AU - Marmé, Frederik

AU - Pantel, Klaus

AU - Jäger, Dirk

AU - Sohn, Christof

AU - Trumpp, Andreas

AU - Wallwiener, Markus

AU - Schneeweiss, Andreas

PY - 2019/1

Y1 - 2019/1

N2 - PURPOSE: Serial longitudinal enumeration of circulating tumor cells (CTCs) has shown its prognostic value on progression-free survival and overall survival (OS) in patients with stage IV breast cancer. This study prospectively evaluated the role of CTCs as a prognostic marker during further progression of metastatic breast cancer (MBC).METHODS: Among 476 MBC patients recruited between 2010 and 2015, the 103 patients with a known CTC status at baseline (CTCBL) and within 4 weeks of tumor progression (CTCPD) were included. Progressive disease (PD) was defined according to the Response Evaluation Criteria in Solid Tumors (RECIST, version 1.1). Using the CellSearch method, < 5 and ≥ 5 CTCs per 7.5 ml blood were determined as negative and positive, respectively. A shift in CTC status from baseline to progression ([Formula: see text] to [Formula: see text] and vice versa) was considered as alternating KineticsBL-PD.RESULTS: Median follow-up was 29.9 [21.2, 40.0] months. CTCPD positivity (37%, n = 38) was associated with a significantly shorter OS than CTCPD negativity (8.0 [5.1, 10.9] vs 22.6 [15.3, 39.8] months; P < 0.001). Alternating KineticsBL-PD was observed in 24% of the patients. This significantly changed the OS prediction of [Formula: see text] patients ([Formula: see text] vs [Formula: see text], 11.4 [9.7, not available (NA)] vs. 7.6 [4.4, 11.5] months; P = 0.044) and [Formula: see text] patients ([Formula: see text] vs. [Formula: see text], 8.4 [4.0, NA] vs. 22.6 [18.9, NA] months, respectively; P < 0.001). Prediction of survival was significantly improved (P = 0.002) by adding CTCPD status to clinicopathological characteristics and CTCBL status.CONCLUSIONS: CTC status upon further disease progression is a prognostic factor that could significantly improve well-established models. Thus, it represents a potential additional instrument supporting treatment decision.

AB - PURPOSE: Serial longitudinal enumeration of circulating tumor cells (CTCs) has shown its prognostic value on progression-free survival and overall survival (OS) in patients with stage IV breast cancer. This study prospectively evaluated the role of CTCs as a prognostic marker during further progression of metastatic breast cancer (MBC).METHODS: Among 476 MBC patients recruited between 2010 and 2015, the 103 patients with a known CTC status at baseline (CTCBL) and within 4 weeks of tumor progression (CTCPD) were included. Progressive disease (PD) was defined according to the Response Evaluation Criteria in Solid Tumors (RECIST, version 1.1). Using the CellSearch method, < 5 and ≥ 5 CTCs per 7.5 ml blood were determined as negative and positive, respectively. A shift in CTC status from baseline to progression ([Formula: see text] to [Formula: see text] and vice versa) was considered as alternating KineticsBL-PD.RESULTS: Median follow-up was 29.9 [21.2, 40.0] months. CTCPD positivity (37%, n = 38) was associated with a significantly shorter OS than CTCPD negativity (8.0 [5.1, 10.9] vs 22.6 [15.3, 39.8] months; P < 0.001). Alternating KineticsBL-PD was observed in 24% of the patients. This significantly changed the OS prediction of [Formula: see text] patients ([Formula: see text] vs [Formula: see text], 11.4 [9.7, not available (NA)] vs. 7.6 [4.4, 11.5] months; P = 0.044) and [Formula: see text] patients ([Formula: see text] vs. [Formula: see text], 8.4 [4.0, NA] vs. 22.6 [18.9, NA] months, respectively; P < 0.001). Prediction of survival was significantly improved (P = 0.002) by adding CTCPD status to clinicopathological characteristics and CTCBL status.CONCLUSIONS: CTC status upon further disease progression is a prognostic factor that could significantly improve well-established models. Thus, it represents a potential additional instrument supporting treatment decision.

KW - Journal Article

U2 - 10.1007/s10549-018-4972-y

DO - 10.1007/s10549-018-4972-y

M3 - SCORING: Journal article

C2 - 30276763

VL - 173

SP - 155

EP - 165

JO - BREAST CANCER RES TR

JF - BREAST CANCER RES TR

SN - 0167-6806

IS - 1

ER -